Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gentium slips on defibrotide plans

GENT fell $1.41 to $17.23 on Monday after it said it plans to submit

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE